C&R Research Inkomsten in het verleden
Verleden criteriumcontroles 3/6
C&R Research has been growing earnings at an average annual rate of 62.3%, while the Life Sciences industry saw earnings growing at 31.2% annually. Revenues have been growing at an average rate of 15.4% per year. C&R Research's return on equity is 11.4%, and it has net margins of 8.8%.
Belangrijke informatie
62.3%
Groei van de winst
125.2%
Groei van de winst per aandeel
| Life Sciences Groei van de industrie | 53.7% |
| Inkomstengroei | 15.4% |
| Rendement op eigen vermogen | 11.4% |
| Nettomarge | 8.8% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe C&R Research geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 58,402 | 5,148 | 50,102 | 0 |
| 31 Mar 24 | 56,853 | 4,813 | 48,775 | 0 |
| 31 Dec 23 | 55,102 | 5,549 | 46,308 | 0 |
| 30 Sep 23 | 51,562 | 4,029 | 44,348 | 0 |
| 30 Jun 23 | 50,615 | 4,364 | 43,287 | 0 |
| 31 Mar 23 | 49,674 | 3,780 | 43,139 | 0 |
| 31 Dec 22 | 48,473 | 4,021 | 41,806 | 0 |
| 30 Sep 22 | 46,857 | -2,163 | 40,479 | 0 |
| 30 Jun 22 | 45,532 | -2,614 | 39,726 | 0 |
| 31 Mar 22 | 44,986 | -3,517 | 37,620 | 0 |
| 31 Dec 21 | 43,171 | -3,301 | 35,742 | 0 |
| 31 Dec 19 | 27,203 | -1,682 | 26,302 | 0 |
Kwaliteitswinsten: A359090 has high quality earnings.
Groeiende winstmarge: A359090's current net profit margins (8.8%) are higher than last year (8.6%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: A359090's earnings have grown significantly by 62.3% per year over the past 5 years.
Versnelling van de groei: A359090's earnings growth over the past year (18%) is below its 5-year average (62.3% per year).
Winst versus industrie: A359090 earnings growth over the past year (18%) did not outperform the Life Sciences industry 18%.
Rendement op eigen vermogen
Hoge ROE: A359090's Return on Equity (11.4%) is considered low.